25 January, 2021

Ziccum extends evaluation agreement with global pharmaceutical company

Lund, January 25, 2021 — Ziccum AB (publ) (‘Ziccum’) entered into an evaluation study agreement on 3 Oct 2019 with Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Based on positive results from the initial phase of studying compatibility with a model vaccine technology platform, both companies have now extended the study agreement until June 30, 2021. This is to finalize the analysis of Ziccum’s air-drying capabilities on one of Janssen’s vaccine platform technologies.

“We’re very proud to extend this first pilot project with Janssen”, says Ziccum CEO Göran Conradson.

“The first pilot project collaboration turned out well”,  Ziccum’s Chairman Fredrik Sjövall points out. “We are of course delighted that we are now extending this collaboration.”

LaminarPaceTM enables the air-drying of delicate biologic drugs such as proteins, peptides and vaccines at room temperature, keeping the active ingredient intact. This capability could enable the development of new, stable, dry powder formulations of vaccines and biologic therapies that can be transported and administered cost-effectively to any climate in the world. In this extended collaboration each party covers their own costs.